Literature DB >> 12119414

Regional analysis of p53 mutations in rheumatoid arthritis synovium.

Yuji Yamanishi1, David L Boyle, Sanna Rosengren, Douglas R Green, Nathan J Zvaifler, Gary S Firestein.   

Abstract

The p53 tumor suppressor protein plays a central role in cell cycle regulation, DNA repair, and apoptosis. Recent studies indicate that DNA damage and somatic mutations in the p53 gene can occur because of genotoxic stress in many tissues, including the skin, colon, and synovium. Although somatic mutations in the p53 gene have been demonstrated in rheumatoid arthritis (RA) synovial tissue and synoviocytes, no information is available on the location or extent of p53 mutations. Using microdissected RA synovial tissue sections, we observed abundant p53 transition mutations, which are characteristic DNA damage caused by oxidative stress. p53 mutations, as well as p53 mRNA expression, were located mainly in the synovial intimal lining rather than the sublining (P < 0.01). Clusters of p53 mutant subclones were observed in some microdissected regions, suggesting oligoclonal expansion. Because IL-6 gene expression is regulated by wild-type p53, IL-6 mRNA expression in microdissected tissues was quantified by using real-time PCR. The regions with high rates of p53 mutations contained significantly greater amounts of IL-6 mRNA compared with the low mutation samples (P < 0.02). The microdissection findings suggest that p53 mutations are induced in RA synovial tissues by inflammatory oxidative stress. This process, as in sun-exposed skin and inflamed colonic epithelium, provides some of the mutant clones with a selective growth advantage. A relatively low percentage of cells containing p53 mutations can potentially affect neighboring cells and enhance inflammation through the elaboration of proinflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12119414      PMCID: PMC126618          DOI: 10.1073/pnas.152333199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovial fibroblasts.

Authors:  F Kullmann; M Judex; I Neudecker; S Lechner; H P Jüsten; D R Green; D Wessinghage; G S Firestein; S Gay; J Schölmerich; U Müller-Ladner
Journal:  Arthritis Rheum       Date:  1999-08

Review 2.  Pathogenesis of rheumatoid arthritis: the role of synoviocytes.

Authors:  Y Yamanishi; G S Firestein
Journal:  Rheum Dis Clin North Am       Date:  2001-05       Impact factor: 2.670

Review 3.  Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases.

Authors:  P P Tak; N J Zvaifler; D R Green; G S Firestein
Journal:  Immunol Today       Date:  2000-02

4.  Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion.

Authors:  T Pap; K R Aupperle; S Gay; G S Firestein; R E Gay
Journal:  Arthritis Rheum       Date:  2001-03

5.  Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium.

Authors:  M Inazuka; T Tahira; T Horiuchi; S Harashima; T Sawabe; M Kondo; H Miyahara; K Hayashi
Journal:  Rheumatology (Oxford)       Date:  2000-03       Impact factor: 7.580

6.  Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease.

Authors:  S P Hussain; P Amstad; K Raja; S Ambs; M Nagashima; W P Bennett; P G Shields; A J Ham; J A Swenberg; A J Marrogi; C C Harris
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

7.  IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.

Authors:  L A Joosten; M M Helsen; T Saxne; F A van De Loo; D Heinegard; W B van Den Berg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

8.  p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis.

Authors:  P P Tak; T J Smeets; D L Boyle; M C Kraan; Y Shi; S Zhuang; N J Zvaifler; F C Breedveld; G S Firestein
Journal:  Arthritis Rheum       Date:  1999-05

9.  Apoptosis in rheumatoid arthritis--expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues.

Authors:  C T Chou; J S Yang; M R Lee
Journal:  J Pathol       Date:  2001-01       Impact factor: 7.996

10.  HPRT- mutant T cells in the peripheral blood and synovial tissue of patients with rheumatoid arthritis.

Authors:  J L Cannons; J Karsh; H C Birnboim; R Goldstein
Journal:  Arthritis Rheum       Date:  1998-10
View more
  75 in total

Review 1.  A question of transformation: the synovial fibroblast in rheumatoid arthritis.

Authors:  Laurie S Davis
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

2.  An essential role of NF-kappaB in the "tumor-like" phenotype of arthritic synoviocytes.

Authors:  Xiangli Li; Sergei S Makarov
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

Review 3.  The Tumor-Like Phenotype of Rheumatoid Synovium: Molecular Profiling and Prospects for Precision Medicine.

Authors:  Sungyong You; Jung Hee Koh; Lin Leng; Wan-Uk Kim; Richard Bucala
Journal:  Arthritis Rheumatol       Date:  2018-03-31       Impact factor: 10.995

Review 4.  Inflammation in 2017: Connectivity to other fields brings new ideas.

Authors:  Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2018-01-11       Impact factor: 20.543

Review 5.  Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

Authors:  Johannes Mischinger; Eva Comperat; Christian Schwentner; Arnulf Stenzl; Georgios Gakis
Journal:  Curr Urol Rep       Date:  2015-09       Impact factor: 3.092

Review 6.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

7.  A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.

Authors:  Anja Fritsch; Stefan Loeckermann; Johannes S Kern; Attila Braun; Michael R Bösl; Thorsten A Bley; Hauke Schumann; Dominik von Elverfeldt; Dominik Paul; Miriam Erlacher; Dirk Berens von Rautenfeld; Ingrid Hausser; Reinhard Fässler; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

8.  The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response.

Authors:  M Leech; J R Xue; A Dacumos; P Hall; L Santos; Y Yang; M Li; A R Kitching; E F Morand
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

9.  Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network.

Authors:  Gang Guo; Luis Marrero; Paulo Rodriguez; Luis Del Valle; Augusto Ochoa; Yan Cui
Journal:  Cancer Res       Date:  2013-01-14       Impact factor: 12.701

10.  Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes.

Authors:  R Chauhan; R Handa; T P Das; U Pati
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.